Basic scientific mechanisms of accelerated development of squamous cell carcinoma in organ transplant recipients

Skin Disease in Organ Transplantation

Volumn , Issue , 2008, Pages 53-59

  Carucci, John A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872913624     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547379.012     Document Type: Chapter

References (48)

1. (UNOS) UNOS database www.UNOS.ORG
2. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. Jul 2002;47(1):1–17.
3. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. Apr 1996;1(2): 136–42.
4. Leffell DJ, Brash DE. Sunlight and skin cancer. Sci Am. Jul 1996;275(1):52–53, 56–59.
5. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle. Feb 2004;3(2):134–7.
6. Samuel T, Weber HO, Funk JO. Linking DNA damage to cell cycle checkpoints. Cell Cycle. May-Jun 2002;1(3):162–8.
7. Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. Dec 1998;4(12):1099–1109.
8. Leversha MA, Fielding P, Watson S, Gosney JR, Field JK. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol. Aug 2003;200(5):610–619.
9. Nindl I, Meyer T, Schmook T, et al Human papillomavirus and over-expression of P16INK4a in nonmelanoma skin cancer. Dermatol Surg. Mar 2004;30(3):409–14.
10. Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Semin Cancer Biol. Feb 2004;14(1):63–9.
11. Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci. Apr 27 1998;3:d447–448.
12. Haider AS, Peters SB, Kaporis H, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. Apr 2006;126(4):869–81.
13. Mercurio AM. Invasive skin carcinoma – Ras and alpha6beta4 integrin lead the way. Cancer Cell. Mar 2003;3(3):201–2.
14. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog. 1991;4(3):196–202.
15. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcino-genesis. Cancer Res. Dec 15 2004;64(24):8804–07.
16. Bell S, Degitz K, Quirling M, Jilg N, Page S, Brand K. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal. Jan 2003;15(1):1–7.
17. Loercher A, Lee TL, Ricker JL. et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. Sep 15 2004;64(18):6511–23.
18. Dajee M, Lazarov M, Zhang JY, et al. NF-kappaB blockade and on-cogenic Ras trigger invasive human epidermal neoplasia. Nature. Feb 6 2003;421(6923):639–43.
19. 19. Neri A, Fracchiolla NS, Migliazza A, Trecca D, Lombardi L. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma. Sep 1996;23(1–2): 43–8.
20. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
21. Yang F, Zeng Q, Yu G, Li S, Wang CY. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal. 18(5):679–87, 2006 May.
22. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. Jul 2003;94(7):593–97.
23. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Pleiotro-phin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys. Jan 15 2002;397(2):162–71.
24. Wu H, Barusevicius A, Babb J, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. Feb 2005;32(2):125–30.
25. Theunis A, Andre J, Noel JC. Evaluation of the role of genital human papillomavirus in the pathogenesis of ungual squamous cell carcinoma. Dermatology. 1999;198(2):206–8.
26. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplant-associated skin cancers. Der-matol Surg. Apr 2004;30(4 Pt 2):604–9.
27. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. Sep 1 2002;16(17):2252–63.
28. Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Der-matol. Apr 2003;12(2):109–25.
29. Aznavoorian S, Moore BA, Alexander-Lister LD, Hallit SL, Windsor LJ, Engler JA. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Res. Aug 15 2001;61(16):6264–75.
30. Nagavarapu U, Relloma K, Herron GS. Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. J Invest Dermatol. Apr 2002;118(4): 573–81.
31. Ala-aho R, Grenman R, Seth P, Kahari VM. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squa-mous carcinoma cells. Oncogene. Feb 14 2002;21(8):1187–95.
32. Van Themsche C, Alain T, Kossakowska AE, Urbanski S, Potworowski EF, St-Pierre Y. Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo. J Immunol. Sep 15 2004;173(6):3605-11.
33. Zhang J, Shridhar R, Dai Q, et al. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. Oct 1 2004; 64(19):6957-64.
34. Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol. Jul 2005;27(1):5-47.
35. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. Jul 18 2005;202(2):203-7.
36. Steinman RM. The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris). Mar 2003;51(2):59-60.
37. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
38. Terao H, Nakayama J, Urabe A, Hori Y. Immunohistochemical characterization of cellular infiltrates in squamous cell carcinoma and Bowen's disease occurring in one patient. J Dermatol. Jul 1992; 19(7):408–13.
39. Smith KJ, Hamza S, Skelton H. Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin Exp Dermatol. Sep 2004;29(5):505-12.
40. Pardo J, Balkow S, Anel A, Simon MM. Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol. Oct 2002;32(10):2881-87.
41. Schwarz T. Mechanisms of UV-induced immunosuppression. Keio J Med. Dec 2005;54(4):165–71.
42. Piskin G, Bos JD, Teunissen MB. Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res. Jan 2005;296(7):339–42.
43. Yaron I, Yaron R, Oluwole SF, Hardy MA. UVB irradiation of human-derived peripheral blood lymphocytes induces apoptosis but not T-cell anergy: additive effects with various immunosuppressive agents. Cell Immunol. Mar 15 1996;168(2):258–66.
44. Carucci JA. Cutaneous oncology in organ transplant recipients: meeting the challenge of squamous cell carcinoma. J Invest Dermatol. Nov 2004;123(5):809–16.
45. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratino-cytes following ultraviolet B irradiation. J Invest Dermatol. Nov 2005;125(5):1020–25.
46. Takahashi T, Kamimura A. Cyclosporin a promotes hair epithelial cell proliferation and modulates protein kinase C expression and translo-cation in hair epithelial cells. J Invest Dermatol. Sep 2001;117(3):605–11.
47. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci. Sep 1996;12(3):246–54.
48. Santini MP, Talora C, Seki T, Bolgan L, Dotto GP. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci U S A. Aug 14 2001;98(17):9575–80.